Glass House Brands (GLAS) Non-Current Deffered Revenue (2020 - 2021)
Glass House Brands' (GLAS) quarterly Non-Current Deffered Revenue came in at $16.1 million in Q1 2021, little changed on a QoQ basis from $16.1 million in Q4 2020.
Glass House Brands (GLAS) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends
Glass House Brands (GLAS) has 2 years of Non-Current Deffered Revenue data on file, last reported at $16.1 million in Q1 2021.
- On a quarterly basis, Non-Current Deffered Revenue changed N/A year-over-year to $16.1 million in Q1 2021; TTM through Mar 2021 was $16.1 million, a N/A change from a year earlier, with the FY2020 full-year figure at $16.1 million, changed N/A from the prior year.
- Non-Current Deffered Revenue for Q1 2021 stood at $16.1 million, roughly flat from $16.1 million in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for GLAS reached as high as $16.1 million in Q4 2020 and fell as low as $16.1 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 16.10 Mn |
| Dec 31, 2020 | 16.10 Mn |